At Palau, our objective is clear: To become an international leader in the discovery and development of small molecule therapeutics for inflammatory and autoimmune conditions.

Our core business model is based on identifying unmet medical needs, and then develop novel drugs through Phase IIa (proof-of-concept) clinical trials. At that point, decisions are made on a case-by-case basis as to whether we keep the development in-house or partner for late-stage development and commercialization.

Based on a unique and high-quality cost-effective structure, we develop "best-in-class" or "first-in-class" drugs that modulate the activity of validated targets with established preclinical or clinical proof-of-concept. Our final objective is to achieve early positive differentiation from our competitor's molecules by addressing their limitations and designing a clear, focused and fast path to commercial success.

Our primary focus is on inflammatory and autoimmune diseases, however, we consider other therapeutic fields, such as oncology, where there are synergies and commercial opportunities with existing development projects.